Burcon NutraScience Corp BRCNF
—
1.00
0.09
9.89%
as of 25 Sep
- Market cap
- —
- P/E
- 0.0×
Follow BRCNF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.52 | 10.76 | 14.43 | 38.18 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.13) | (8.11) | (14.10) | (15.41) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 235.61 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
15.40 | 20.98 | 28.67 | 70.04 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 526.60 | |
EV/Operating CF |
(5.55) | (5.18) | (0.75) | (0.99) | |
EV/FCF |
(5.06) | (4.69) | (0.70) | (0.94) | |
Quick Ratio |
0.14 | 0.13 | 0.14 | 0.19 | |
Current Ratio |
0.21 | 0.19 | 0.22 | 0.25 | |
Net Debt/EBITDA |
(8.66) | (7.58) | (8.30) | (2.92) | |
Debt/Assets |
112.51% | 104.77% | 93.56% | 33.58% | |
Debt/Equity |
(2.88) | (4.15) | (9.02) | 63.86 | |
Asset Turnover |
0.13 | 0.08 | 0.09 | 0.05 | |
Operating CF/Net income |
0.63 | 0.83 | 0.42 | 0.55 | |
Capex/Depreciation |
(0.25) | (0.55) | (1.02) | (0.76) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
18.25% | (5.48%) | 51.34% | 106.29% | |
Selling, General and Administrative Expense of Revenue |
61.73% | 87.07% | 93.68% | 216.97% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
16.20% | 17.33% | 13.71% | 47.09% | |
Graham Net Nets |
(1.21) | (1.08) | (1.11) | (0.71) | |
Graham Number |
3.12 | 2.47 | 1.56 | 0.00 | |
Earnings Yield |
(61.31%) | (58.99%) | (63.64%) | (44.25%) | |
Free Cash Flow Yield |
(40.49%) | (41.53%) | (283.07%) | (196.05%) | |
Revenue per Share |
0.07 | 0.05 | 0.04 | 0.02 | |
Operating CF per Share |
(0.14) | (0.17) | (0.09) | (0.11) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.03) | |
Free Cash Flow per Share |
(0.14) | (0.18) | (0.09) | (0.14) | |
Cash per Share |
0.05 | 0.05 | 0.07 | 0.10 | |
Shareholders Equity per Share |
(0.52) | (0.33) | (0.14) | 0.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.52) | (0.33) | (0.14) | 0.01 | |
Free Cash Flow |
(1.76) | (2.29) | (1.18) | (1.81) | |
Working Capital |
(8.11) | (7.66) | (6.95) | (5.96) | |
Capital Expenditures |
(0.04) | (0.12) | (0.09) | (0.38) | |
Net Current Asset Value |
(21.12) | (19.08) | (17.04) | (15.71) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.20 | 0.16 | 1.46 | |
Net Profit Margin |
(295.90%) | (436.86%) | (483.72%) | (1,005.90%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.61 | 0.30 | 0.19 | 0.26 | |
Average Payables |
1.29 | 1.21 | 1.04 | 0.77 | |
Average Inventory |
0.41 | 0.26 | 0.38 | 0.24 | |
Average Assets |
18.13 | 19.34 | 11.65 | 12.41 | |
Average Common Equity |
(1.97) | 0.40 | (0.92) | 0.65 |
Columns are period end dates